Placebo: Clinical Trials

10,911 trials of Placebo, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6787 completed, 1157 terminated, 929 recruiting, 802 unknown. 10911 Phase 3, 1583 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 310911Completed 6787, Terminated 1157, Recruiting 929, Unknown 802, Active not recruiting 565, Withdrawn 333, Not yet recruiting 290, Suspended 28, Enrolling by invitation 20
Phase 21583Completed 892, Unknown 210, Terminated 172, Recruiting 122, Withdrawn 72, Not yet recruiting 53, Active not recruiting 52, Enrolling by invitation 6, Suspended 4

Follow Placebo: new trials by email Literature Review of Placebo trials Research Report on Placebo

Trials (filtered) newest first · largest first

All 10,911 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Clinical Study of DA-007 for the Treatment of Chemotherapy Induced Alopecia
DA-007, Placebo - Chemotherapy Induced Alopecia, Chemotherapy Side Effects
Phase 3Not yet recruitingApplied Biology, Inc.1402027-10-102026-11-02
Dantrolene in Statin-induced Myopathy
Dantrolene, Placebo - Statins Induced Myopathy
Phase 2 / Phase 3Not yet recruitingTanta University232027-10-012025-05-13
Aspirin for the Prevention of Ischemic Complications in Giant Cell Arteritis
Acetyl Salicylic Acid (ASA), Placebo - Giant Cell Arteritis (GCA), Acute Coronary Syndrome (ACS)
Phase 3Not yet recruitingCentre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal1202027-10-012026-10-30
Astragalus for Symptomatic Alleviation in High-grade Lymphoma
Astragalus, Placebo - High-grade Lymphoma
Phase 3Not yet recruitingBnai Zion Medical Center602027-08-012026-09-30
Efficacy and Safety of GNSC-001 Intra-articular Injection for Knee Osteoarthritis
Gene Therapy GNSC-001, Placebo - Knee Arthritis Osteoarthritis, Knee Arthritis, Osteoarthritis
Phase 2 / Phase 3Not yet recruitingGenascence Corporation2402027-07-012026-09-21
Efficacy and Safety of NTI164 in Children and Young Adults With Rett Syndrome
NTI164, Placebo - RETT Syndrome With Proven MECP2 Mutation, Rett Syndrome
Phase 2 / Phase 3Not yet recruitingFenix Innovation Group402027-07-012026-09-09
Tricaprilin Phase 3 ALTER-AD (Alternative-Alzheimer Disease) Study
Tricaprilin, Placebo - Alzheimer Disease
Phase 3Not yet recruitingCerecin5352027-07-012026-10-30
Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma
Sugemalimab, Placebo, Pegaspargase - Extranodal NK/T-cell Lymphoma
Phase 3Not yet recruitingCStone Pharmaceuticals1502027-06-012026-05-27
Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery
Moxifloxacin, Placebo - Endophthalmitis
Phase 2 / Phase 3Not yet recruitingJason Ahee, M.D.600002027-06-012026-09-15
Fighting Osteoporosis With Risedronate Co-Therapy During Incretin
Tirzepatide, Risedronate, Placebo - Obesity
Phase 3Not yet recruitingWake Forest University Health Sciences962027-06-012026-11-17
Abrocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Years of Age
Abrocitinib, Placebo - Atopic Dermatitis
Phase 3Not yet recruitingPfizer902027-05-012026-09-16
Semaglutide in Alcohol Use Disorder
Wegovy, Placebo - Alcohol Use Disorder (AUD), Obesity
Phase 3Not yet recruitingUniversity of Minnesota1282027-05-012026-11-19
Intranasal Stem Cells to Treat Perinatal Brain Injury to Combat Cerebral Palsy
MSC, marrow, Placebo - Perinatal Arterial Ischemic Stroke, Perinatal Asphyxia
Phase 2 / Phase 3Not yet recruitingUMC Utrecht1622027-04-012026-09-21
A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592) for Treating Anemia in Participants With Myelodysplastic Syndromes (MDS)
Roxadustat, Placebo - Myelodysplastic Syndromes
Phase 3Not yet recruitingKyntra Bio2012027-04-012026-07-23
Cardiovascular and Renal Protection With SGLT Inhibition in Kidney Transplant Recipients: The RENAISSANCE Trial
Sotagliflozin, Placebo - Kidney Transplant Recipient
Phase 3Not yet recruitingUniversity of British Columbia9002027-04-012026-11-18
Reducing Arterial Inflammation Using Eplerenone and Statins in HIV
Eplerenone, Placebo - HIV (Human Immunodeficiency Virus), Cardiovascular Diseases (CVD)
Phase 2 / Phase 3Not yet recruitingMassachusetts General Hospital1242027-03-012026-10-23
Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma
Safusidenib, Placebo - Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 Mutation, Astrocytoma IDH Mutant Grade 2
Phase 3Not yet recruitingNuvation Bio Inc.1402027-03-012026-07-17
Individualized Prolonged Luteal Support After Fresh Embryo Transfer in Women With Low Progesterone
Progesterone Injectable, Placebo, Progesterone Vaginal Suppository - Pregnancy, Progesterone Supplementation
Phase 3Not yet recruitingUniversity Hospital, Montpellier2142027-03-012026-06-02
Sotagliflozin to Lower Proteinuria in Recipients of a Kidney Transplant
Sotagliflozin, Placebo - Kidney Transplant, Albuminuria
Phase 3Not yet recruitingFinnian Mc Causland1802027-03-012026-11-18
A Phase 3, Multicenter Study of Vorasidenib in Combination With Temozolomide (TMZ) in Participants With IDH1- or IDH2 Mutant High-grade Astrocytoma.
Vorasidenib, Placebo, Temozolomide (TMZ) - IDH-mutant High-grade Astrocytoma
Phase 3Not yet recruitingInstitut de Recherches Internationales Servier5502027-03-012026-11-17

Showing 20 of 10911. Sign in to see all of them.

Conditions studied

Diabetes Mellitus, Type 2 (415)  ·  COVID-19 (323)  ·  Obesity (247)  ·  Pain (231)  ·  Diabetes Mellitus (185)  ·  Pulmonary Disease, Chronic Obstructive (177)  ·  Depressive Disorder, Major (171)  ·  Asthma (167)  ·  Breast Neoplasms (156)  ·  Depression (152)  ·  Schizophrenia (135)  ·  Alzheimer Disease (134)  ·  Carcinoma, Non-Small-Cell Lung (131)  ·  Overweight (123)  ·  Attention Deficit Disorder with Hyperactivity (121)

Sponsors

Eli Lilly and Company (294)  ·  AstraZeneca (244)  ·  Novartis Pharmaceuticals (233)  ·  Pfizer (193)  ·  GlaxoSmithKline (190)  ·  Hoffmann-La Roche (157)  ·  Sanofi (152)  ·  Merck Sharp & Dohme LLC (140)  ·  Boehringer Ingelheim (138)  ·  Takeda (129)  ·  Amgen (122)  ·  Bayer (111)  ·  Janssen Research & Development, LLC (107)  ·  Assistance Publique - Hôpitaux de Paris (96)  ·  Novo Nordisk A/S (70)

Countries

United States (5507)  ·  Canada (2379)  ·  Germany (2369)  ·  Spain (2110)  ·  France (2088)  ·  United Kingdom (1964)  ·  Italy (1870)  ·  Poland (1869)  ·  Australia (1534)  ·  China (1532)  ·  Belgium (1364)  ·  South Korea (1326)  ·  Japan (1313)  ·  Czechia (1232)  ·  Netherlands (1190)

Results publications

PMID 38770818, PMID 34473343, PMID 39963952, PMID 33687069, PMID 37142273, PMID 40576086, PMID 31903692, PMID 32816215, PMID 35713300, PMID 37811711, PMID 39356039, PMID 32998732, PMID 36526796, PMID 36931693, PMID 37316690, PMID 40603145, PMID 22913891, PMID 25019647, PMID 31606880, PMID 33078867, PMID 34611902, PMID 35224730, PMID 37160401, PMID 37460782, PMID 24517339, PMID 24786834, PMID 26580237, PMID 32267058, PMID 33710614, PMID 34795131, PMID 34870800, PMID 34921355, PMID 36005278, PMID 36814062, PMID 37230961, PMID 38979716, PMID 22236356, PMID 27338778, PMID 27402391, PMID 29685591, PMID 30936738, PMID 31081589, PMID 31319851, PMID 32943047, PMID 33826132, PMID 33874971, PMID 35277540, PMID 35305260, PMID 35472672, PMID 37185961

NIH funding

2023 (246), 2015 (146), 2017 (134), 2018 (132), 2025 (129), 2016 (124), 2014 (118), 2019 (105), 2009 (104), 2008 (101), 2005 (36), 2004 (24), U10HD021373 (9), U10HD021385 (9), U10HD027880 (8)